Activities of ABT-773 against
            <i>Listeria monocytogenes</i>
            and Coryneform Bacteria of Clinical Interest

Conejo, M. Carmen; Martínez-Martínez, Luis; Pascual, Álvaro; Suárez, A.; Perea, Evelio J.

doi:10.1128/aac.47.4.1403-1406.2003

Cited by 3 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of C. urealyticum strains obtained from clinical samples typically display multiple resistance to antibiotics [19,30,31]. C. urealyticum is normally highly resistant to β‐lactams and aminoglycosides, and variably susceptible to fluoroquinolones, macrolides, ketolides, rifampin, and tetracyclines [5,32–44]. C. urealyticum strains are, however, uniformly susceptible to the glycopeptides vancomycin and teicoplanin [5,31,35,37,39,41,43].…”

Section: Antimicrobial Susceptibilitymentioning

confidence: 99%

“…Newer fluoroquinolones, such as clinafloxacin, gemifloxacin, levofloxacin, and ofloxacin, are more effective in vitro than ciprofloxacin and norfloxacin, but may remain ineffective against high‐level ciprofloxacin‐resistant isolates [40,41,43,48]. Likewise, the ketolide telithromycin is more active in vitro than the macrolide erythromycin, but only against erythromycin‐susceptible and erythromycin‐intermediate isolates [39,40,43], whereas the ketolide cethromycin (ABT‐773) is only poorly active against C. urealyticum [42]. On the other hand, newer antibiotics, such as linezolid and quinupristin–dalfopristin, proved to be effective in vitro against C. urealyticum strains [39,43,44].…”

Section: Antimicrobial Susceptibilitymentioning

confidence: 99%

See 1 more Smart Citation

Microbiological and clinical features of Corynebacterium urealyticum: urinary tract stones and genomics as the Rosetta Stone

Soriano

Tauch

2008

Clinical Microbiology and Infection

100

View full text Add to dashboard Cite

Corynebacterium urealyticum, formerly known as coryneform CDC group D2, was first recognized to be involved in human infections 30 years ago. It is a slow-growing, lipophilic, asaccharolytic and usually multidrug-resistant organism with potent urease activity. Its cell wall peptidoglycan, menaquinone, mycolic and cellular fatty acid composition is consistent with that of the genus Corynebacterium. DNA-DNA hybridization studies and 16S rDNA sequencing analysis have been used to determine the degree of relatedness of C. urealyticum to other corynebacterial species. The genome of the type strain consists of a circular chromosome with a size of 2 369 219 bp and a mean G + C content of 64.2%, and analysis of its genome explains the bacterium's lifestyle. C. urealyticum is a common skin colonizer of hospitalized elderly individuals who are receiving broad-spectrum antibiotics. It is an opportunistic pathogen causing mainly acute cystitis, pyelonephritis, encrusted cystitis, and encrusted pyelitis. More infrequently, it causes other infections, but mainly in patients with urological diseases. Infections are more common in males than in females, and treatment requires administration of antibiotics active against the organism in vitro, mainly glycopeptides, as well as surgical intervention, the latter mostly in cases of chronic infection. Mortality directly associated with infection by this organism is not frequent, but encrusted pyelitis in kidney-recipient patients may cause graft loss. The outcome of infection by this organism is reasonably good if the microbiological diagnosis is made and patients are treated appropriately.

show abstract

Section: Antimicrobial Susceptibilitymentioning

confidence: 99%

Section: Antimicrobial Susceptibilitymentioning

confidence: 99%

Microbiological and clinical features of Corynebacterium urealyticum: urinary tract stones and genomics as the Rosetta Stone

Soriano

Tauch

2008

Clinical Microbiology and Infection

100

View full text Add to dashboard Cite

show abstract

“…Additionally there is a variable activity of tetracyclines ( 26 , 84 , 85 ) and rifampin ( 26 , 43 , 84 ) and a reasonable activity of fusidic acid ( 43 , 84 , 91 ). CU is however highly resistant to penicillins, cephalosporins, carbapenems, lincosamides, aminoglycosides, macrolides, ketolides, sulphonamides, nitrofurantoin, fosfomycin, chloramphenicol, and trimethoprim-sulfamethoxazole ( 24 , 40 , 84 – 86 , 92 ).…”

Section: Treatmentmentioning

confidence: 99%

Encrusted Uropathy: A Comprehensive Overview—To the Bottom of the Crust

et al. 2021

View full text Add to dashboard Cite

Encrusted uropathy is a rare subacute to chronic inflammatory disorder caused by infection with urease-producing bacteria, mainly Corynebacterium urealyticum. The disorder is characterized by urothelial deposition of struvite and carbonated apatite, resulting in encrustations and ulceronecrotic inflammation of the urothelium and surrounding tissues. Most commonly, encrusted uropathy is encountered in patients with predisposing conditions. The disease remains underdiagnosed. High urinary pH and negative conventional urine cultures should raise suspicion of the diagnosis. Prognosis is dependent on timely diagnosis and treatment installment, which consists of urological removal of encrustations in combination with urinary acidification and long-term antibiotic therapy.

show abstract

Steady-State Plasma and Intrapulmonary Pharmacokinetics and Pharmacodynamics of Cethromycin

Conte

Golden²,

Kipps³

et al. 2004

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The objective of this study was to determine the steady-state plasma and intrapulmonary pharmacokinetic parameters of orally administered cethromycin in healthy volunteers. The study design included administering 150 or 300 mg of cethromycin once daily to 25 or 35 healthy adult subjects, respectively, for a total of five doses. Standardized and timed bronchoalveolar lavage (BAL) was performed after the last dose. Blood was obtained for drug assay prior to the first and last dose, at multiple time points following the last dose, and at the time of BAL. Cethromycin was measured in plasma, BAL, and alveolar cell (AC) by using a combined high-performance liquid chromatography-mass spectrometric technique. Plasma, epithelial lining fluid (ELF), and AC pharmacokinetics were derived by noncompartmental methods. C max /90% minimum inhibitory concentration (MIC 90 ) ratios, area under the concentration-time curve (AUC)/MIC 90 ratios, intrapulmonary drug exposure ratios, and percent time above MIC 90 during the dosing interval (%T > MIC 90 ) were calculated for recently reported respiratory pathogens. The kinetics were nonlinear, i.e., not proportional to dose. In the 150-mg-dose group, the C max (mean ؎ standard deviations), AUC 0-24 , and half-life for plasma were 0.181 ؎ 0.084 g/ml, 0.902 ؎ 0.469 g · h/ml, and 4.85 ؎ 1.10 h, respectively; for ELF the values were 0.9 ؎ 0.2 g/ml, 11.4 g · h/ml, and 6.43 h, respectively; for AC the values were 12.7 ؎ 6.4 g/ml, 160.8 g · h/ml, and 10.0 h, respectively. In the 300-mg-dose group, the C max (mean ؎ standard deviations), AUC 0-24 , and half-life for plasma were 0.500 ؎ 0.168 g/ml, 3.067 ؎ 1.205 g · h/ml, and 4.94 ؎ 0.66 h, respectively; for ELF the values were 2.7 ؎ 2.0 g/ml, 24.15 g · h/ml, and 5.26 h, respectively; for AC the values were 55.4 ؎ 38.7 g/ml, 636.2 g · h/ml, and 11.6 h, respectively. We concluded that the C max /MIC 90 ratios, AUC/MIC 90 ratios, %T > MIC 90 values, and extended plasma and intrapulmonary half-lives provide a pharmacokinetic rationale for once-daily administration and are favorable for the treatment of cethromycin-susceptible pulmonary infections.Cethromycin is an investigational ketolide antibiotic that is active against common respiratory pathogens, such as Streptococcus pneumoniae, Mycoplasma pneumoniae, Chlamydia pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, group A streptococci, and Streptococcus viridans (14,15,17,18,29). Cethromycin is also active, in vitro and in a murine model, against Mycobacterium avium infection (10), and related macrolides are active against other mycobacteria (12, 21). Doses of cethromycin ranging from 100 to 1,200 mg have been administered to humans in phase I clinical studies. The plasma elimination half-life (t 1/2 ) ranges from 3.6 to 6.7 h (R. S. Pradhan, L. E. Gustavson, D. D. Londo, Y. Shang, J. Zhang, and M. Paris, Abstr. 40th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 2138, 2000). The maximum concentration of drug in serum (C max ), area under the concentration-time curve from 0 to 24...

show abstract

Activities of ABT-773 against Listeria monocytogenes and Coryneform Bacteria of Clinical Interest

Cited by 3 publications

References 23 publications

Microbiological and clinical features of Corynebacterium urealyticum: urinary tract stones and genomics as the Rosetta Stone

Microbiological and clinical features of Corynebacterium urealyticum: urinary tract stones and genomics as the Rosetta Stone

Encrusted Uropathy: A Comprehensive Overview—To the Bottom of the Crust

Steady-State Plasma and Intrapulmonary Pharmacokinetics and Pharmacodynamics of Cethromycin

Contact Info

Product

Resources

About